Abstract
Chronic inflammatory bone diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis and periodontal disease, demonstrate the major impact of chronic inflammation on both bone metabolism and bone architecture. During the past decade, scientists have gained increasing insight into the link between inflammation and bone. As a result of new discoveries about the molecular mechanisms of inflammatory bone loss, several molecules have been identified that are attractive and novel targets for the treatment of inflammatory bone loss. These novel therapeutic approaches include anti-tumor necrosis factor (TNF)-alpha blocking agents, neutralizing antibodies against certain pro-inflammatory cytokines, such as interleukin (IL)-6 and IL-17, and a set of other promising targets that still require extensive research, such as the Wnt signaling network.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / pathology
-
Arthritis, Rheumatoid / therapy
-
Bone Diseases / immunology*
-
Bone Diseases / pathology
-
Bone Diseases / therapy
-
Bone and Bones / immunology
-
Bone and Bones / pathology
-
Humans
-
Inflammation
-
Interleukin-17 / antagonists & inhibitors
-
Interleukin-17 / immunology
-
Interleukin-6 / antagonists & inhibitors
-
Interleukin-6 / immunology
-
Signal Transduction / immunology
-
Spondylitis, Ankylosing / immunology
-
Spondylitis, Ankylosing / pathology
-
Spondylitis, Ankylosing / therapy
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / immunology
-
Wnt Proteins / immunology
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Interleukin-17
-
Interleukin-6
-
Tumor Necrosis Factor-alpha
-
Wnt Proteins